Cargando…
Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management
The recent developments in the study of clustered regularly interspaced short palindromic repeats/associated protein 9 (CRISPR/Cas9) system have revolutionized the art of genome-editing and its applications for cellular differentiation and immune response behavior. This technology has further helped...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547015/ https://www.ncbi.nlm.nih.gov/pubmed/37795042 http://dx.doi.org/10.2147/IJN.S424872 |
_version_ | 1785114975741673472 |
---|---|
author | Allemailem, Khaled S Alsahli, Mohammed A Almatroudi, Ahmad Alrumaihi, Faris Al Abdulmonem, Waleed Moawad, Amira A Alwanian, Wanian M Almansour, Nahlah Makki Rahmani, Arshad Husain Khan, Amjad Ali |
author_facet | Allemailem, Khaled S Alsahli, Mohammed A Almatroudi, Ahmad Alrumaihi, Faris Al Abdulmonem, Waleed Moawad, Amira A Alwanian, Wanian M Almansour, Nahlah Makki Rahmani, Arshad Husain Khan, Amjad Ali |
author_sort | Allemailem, Khaled S |
collection | PubMed |
description | The recent developments in the study of clustered regularly interspaced short palindromic repeats/associated protein 9 (CRISPR/Cas9) system have revolutionized the art of genome-editing and its applications for cellular differentiation and immune response behavior. This technology has further helped in understanding the mysteries of cancer progression and possible designing of novel antitumor immunotherapies. CRISPR/Cas9-based genome-editing is now often used to engineer universal T-cells, equipped with recombinant T-cell receptor (TCR) or chimeric antigen receptor (CAR). In addition, this technology is used in cytokine stimulation, antibody designing, natural killer (NK) cell transfer, and to overcome immune checkpoints. The innovative potential of CRISPR/Cas9 in preparing the building blocks of adoptive cell transfer (ACT) immunotherapy has opened a new window of antitumor immunotherapy and some of them have gained FDA approval. The manipulation of immunogenetic regulators has opened a new interface for designing, implementation and interpretation of CRISPR/Cas9-based screening in immuno-oncology. Several cancers like lymphoma, melanoma, lung, and liver malignancies have been treated with this strategy, once thought to be impossible. The safe and efficient delivery of CRISPR/Cas9 system within the immune cells for the genome-editing strategy is a challenging task which needs to be sorted out for efficient immunotherapy. Several targeting approaches like virus-mediated, electroporation, microinjection and nanoformulation-based methods have been used, but each procedure offers some limitations. Here, we elaborate the recent updates of cancer management through immunotherapy in partnership with CRISPR/Cas9 technology. Further, some innovative methods of targeting this genome-editing system within the immune system cells for reprogramming them, as a novel strategy of anticancer immunotherapy is elaborated. In addition, future prospects and clinical trials are also discussed. |
format | Online Article Text |
id | pubmed-10547015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-105470152023-10-04 Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management Allemailem, Khaled S Alsahli, Mohammed A Almatroudi, Ahmad Alrumaihi, Faris Al Abdulmonem, Waleed Moawad, Amira A Alwanian, Wanian M Almansour, Nahlah Makki Rahmani, Arshad Husain Khan, Amjad Ali Int J Nanomedicine Review The recent developments in the study of clustered regularly interspaced short palindromic repeats/associated protein 9 (CRISPR/Cas9) system have revolutionized the art of genome-editing and its applications for cellular differentiation and immune response behavior. This technology has further helped in understanding the mysteries of cancer progression and possible designing of novel antitumor immunotherapies. CRISPR/Cas9-based genome-editing is now often used to engineer universal T-cells, equipped with recombinant T-cell receptor (TCR) or chimeric antigen receptor (CAR). In addition, this technology is used in cytokine stimulation, antibody designing, natural killer (NK) cell transfer, and to overcome immune checkpoints. The innovative potential of CRISPR/Cas9 in preparing the building blocks of adoptive cell transfer (ACT) immunotherapy has opened a new window of antitumor immunotherapy and some of them have gained FDA approval. The manipulation of immunogenetic regulators has opened a new interface for designing, implementation and interpretation of CRISPR/Cas9-based screening in immuno-oncology. Several cancers like lymphoma, melanoma, lung, and liver malignancies have been treated with this strategy, once thought to be impossible. The safe and efficient delivery of CRISPR/Cas9 system within the immune cells for the genome-editing strategy is a challenging task which needs to be sorted out for efficient immunotherapy. Several targeting approaches like virus-mediated, electroporation, microinjection and nanoformulation-based methods have been used, but each procedure offers some limitations. Here, we elaborate the recent updates of cancer management through immunotherapy in partnership with CRISPR/Cas9 technology. Further, some innovative methods of targeting this genome-editing system within the immune system cells for reprogramming them, as a novel strategy of anticancer immunotherapy is elaborated. In addition, future prospects and clinical trials are also discussed. Dove 2023-09-29 /pmc/articles/PMC10547015/ /pubmed/37795042 http://dx.doi.org/10.2147/IJN.S424872 Text en © 2023 Allemailem et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Allemailem, Khaled S Alsahli, Mohammed A Almatroudi, Ahmad Alrumaihi, Faris Al Abdulmonem, Waleed Moawad, Amira A Alwanian, Wanian M Almansour, Nahlah Makki Rahmani, Arshad Husain Khan, Amjad Ali Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management |
title | Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management |
title_full | Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management |
title_fullStr | Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management |
title_full_unstemmed | Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management |
title_short | Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management |
title_sort | innovative strategies of reprogramming immune system cells by targeting crispr/cas9-based genome-editing tools: a new era of cancer management |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547015/ https://www.ncbi.nlm.nih.gov/pubmed/37795042 http://dx.doi.org/10.2147/IJN.S424872 |
work_keys_str_mv | AT allemailemkhaleds innovativestrategiesofreprogrammingimmunesystemcellsbytargetingcrisprcas9basedgenomeeditingtoolsaneweraofcancermanagement AT alsahlimohammeda innovativestrategiesofreprogrammingimmunesystemcellsbytargetingcrisprcas9basedgenomeeditingtoolsaneweraofcancermanagement AT almatroudiahmad innovativestrategiesofreprogrammingimmunesystemcellsbytargetingcrisprcas9basedgenomeeditingtoolsaneweraofcancermanagement AT alrumaihifaris innovativestrategiesofreprogrammingimmunesystemcellsbytargetingcrisprcas9basedgenomeeditingtoolsaneweraofcancermanagement AT alabdulmonemwaleed innovativestrategiesofreprogrammingimmunesystemcellsbytargetingcrisprcas9basedgenomeeditingtoolsaneweraofcancermanagement AT moawadamiraa innovativestrategiesofreprogrammingimmunesystemcellsbytargetingcrisprcas9basedgenomeeditingtoolsaneweraofcancermanagement AT alwanianwanianm innovativestrategiesofreprogrammingimmunesystemcellsbytargetingcrisprcas9basedgenomeeditingtoolsaneweraofcancermanagement AT almansournahlahmakki innovativestrategiesofreprogrammingimmunesystemcellsbytargetingcrisprcas9basedgenomeeditingtoolsaneweraofcancermanagement AT rahmaniarshadhusain innovativestrategiesofreprogrammingimmunesystemcellsbytargetingcrisprcas9basedgenomeeditingtoolsaneweraofcancermanagement AT khanamjadali innovativestrategiesofreprogrammingimmunesystemcellsbytargetingcrisprcas9basedgenomeeditingtoolsaneweraofcancermanagement |